logoAiPathly

BioAge Labs

B

Leadership Team

BioAge Labs, a clinical-stage biopharmaceutical company, boasts a diverse and experienced leadership team driving its mission to develop therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Key members include:

CEO and Co-Founder

  • Kristen Fortney, PhD: Serving as CEO, President, and Treasurer since April 2015. Her annual compensation is approximately $1.38 million, with a 3.38% direct ownership of company shares.

Co-Founder

  • Eric Morgen: Leads human cohort partnerships and computational efforts for drug target discovery. His background spans artificial intelligence, medicine, and computational biology.

Chief Medical Officer & Executive VP of Research

  • Paul Rubin: Heads clinical development of BioAge's aging-targeted therapies. He brings extensive experience from pharmaceutical and biotech industries.

Chief Financial Officer

  • Dov Goldstein: Brings over 20 years of strategic financial and operational experience in healthcare, having held leadership roles at various biotech companies.

Other Key Positions

  • Chief Business Officer & Therapeutic Area Head of Brain Aging
  • Senior Vice President of Regulatory Affairs
  • Senior Vice President of Translational Aging Biology
  • Chief Strategy Officer

Board of Directors

  • Jean-Pierre Garnier, PhD: Recently appointed Chair, former CEO of GlaxoSmithKline
  • James Healy, MD, PhD: Former Chair, continuing board member and managing partner of Sofinnova Investments The leadership team combines seasoned executives and visionary co-founders, each contributing significant expertise to advance BioAge Labs' innovative approach to treating age-related diseases.

Core Technology

BioAge Labs leverages a data-driven approach to understand and target the biology of human aging, focusing on cardiometabolic and age-related diseases. Their core technology encompasses several key components:

Data Collection and Analysis

BioAge Labs utilizes extensive longitudinal human longevity data, primarily from blood samples, including:

  • Proteomics: Analyzing 5,000 proteins
  • Metabolomics: Examining several thousand metabolites
  • Gene expression: Analyzing tens of thousands of gene expressions using RNA-Seq

AI and Machine Learning

Advanced AI and ML algorithms are employed to analyze the vast dataset, identifying key molecular factors that change with age and predict future health outcomes. This approach distinguishes between healthy and unhealthy aging profiles.

Longitudinal Omics and Functional Assessments

The platform integrates longitudinal omics data with serial functional assessments, modeling aging-related physical, cognitive, and functional decline. This method captures healthspan trajectories starting from healthy individuals.

Discovery and Development

BioAge's platform identifies translational drug targets by analyzing the complex interplay of biological pathways related to metabolic aging. An unbiased approach is used to identify targets, which are then validated through an in-house translational aging core in naturally aged mice.

Collaboration and Integration

The company collaborates with industry leaders like Novartis, combining their human longevity datasets with external expertise to discover and validate new therapeutic drug targets.

Bespoke Data Science Ecosystem

BioAge has developed a custom data science ecosystem utilizing AI and ML to generate insights from human aging cohorts, crucial for identifying and validating potential therapeutic targets. By integrating these elements, BioAge Labs aims to develop therapies targeting fundamental biological pathways of human aging, with the goal of improving health outcomes and increasing healthspan.

Industry Peers

BioAge Labs operates within the biotechnology industry, focusing on aging and age-related metabolic diseases. Key industry peers and competitors include:

UNITY Biotechnology

A significant competitor developing therapeutics targeting diseases of aging, listed on NASDAQ under the ticker symbol UBX.

FibroGen

Known for developing innovative therapeutics in areas such as anemia and fibrosis, aligning with BioAge Labs' focus on metabolic and aging-related diseases.

Amgen

A major biotechnology company with a robust pipeline of therapeutics targeting metabolic diseases, including obesity and related conditions.

Novo Nordisk

A prominent player in the biotechnology sector, with a strong focus on diabetes and obesity treatments, presenting significant competition in the metabolic diseases space.

Regeneron Pharmaceuticals

Known for its innovative approach to drug development, particularly in metabolic disorders, posing a challenge to BioAge Labs with cutting-edge technologies and therapies.

Vertex Pharmaceuticals

While primarily focused on rare diseases and genetic disorders, Vertex presents competition in the broader biotech space due to innovative approaches and significant resources.

Other Competitors

Additional companies in the broader biotechnology and healthcare space that may overlap with BioAge Labs' research areas include:

  • DiaCarta
  • Mission Bio
  • Quadrants Scientific These competitors highlight the dynamic and competitive nature of the aging and metabolic diseases biotechnology sector, driving innovation and advancements in therapeutic development.

More Companies

A

Asian Development Bank

The Asian Development Bank (ADB) is a multilateral development finance institution dedicated to promoting economic growth, social progress, and poverty reduction in the Asia and Pacific region. Established on December 19, 1966, under Japan's leadership, the ADB is headquartered in Manila, Philippines, and comprises 67 members, including 48 regional and 19 non-regional countries. The ADB's primary mission is to foster economic growth and cooperation in the Asia-Pacific Region, aiming to build a prosperous, inclusive, resilient, and sustainable region while eradicating extreme poverty. The bank's operations align with the United Nations' Sustainable Development Goals (SDGs), focusing on key areas such as education, health, transport, energy, finance, and climate change. Financial Assistance and Services: - Loans: Both sovereign and private sector - Grants: For specific development projects - Technical Assistance: Enhancing member countries' capacities - Equity Investments: In private sector and public-private partnership projects - Cofinancing Operations: Mobilizing resources from various sources The ADB's operational structure includes the Board of Governors as its highest policy-making body, with powers delegated to the Board of Directors. Japan and the United States are the largest shareholders. Key Activities and Initiatives: - Policy dialogues and advisory services - Private sector development support - Public-private partnerships - Crisis response (e.g., COVID-19 pandemic support) As of 2020, the ADB reported an overall portfolio of US$116.5 billion and awarded 6,931 development contracts valued at US$10.3 billion. In 2021, the bank committed nearly US$13.5 billion to help its developing member countries address the impacts of the COVID-19 crisis. The ADB collaborates with other international financial institutions, such as the International Monetary Fund (IMF) and the World Bank, to achieve its development goals in the Asia-Pacific region.

Z

Zepto

Zepto is an Indian quick-commerce company that has experienced rapid growth since its inception in 2021. Founded by childhood friends Aadit Palicha and Kaivalya Vohra, the company has revolutionized grocery delivery in India with its innovative approach. ### Business Model and Operations Zepto operates on a "dark store" model, utilizing micro-warehouses strategically located in urban areas to enable fast and efficient delivery. The company's average delivery time is approximately 8 minutes and 47 seconds, achieved through AI-powered inventory management and order fulfillment systems. As of August 2024, Zepto operates over 250 dark stores across ten metropolitan areas in India, including Mumbai, Delhi, Bengaluru, and Chennai. The company has expanded beyond groceries to offer coffee and ready-to-eat food delivery through its Cafe division, as well as launching Bloom, a platform for farmers to manage food production and distribution. ### Funding and Valuation Zepto has secured significant funding through multiple rounds: - Pre-seed round: $730,000 (January 2021) - Series A: $60 million (October 2021) - Series C: $100 million (December 2021) - Series D: $200 million (May 2022) - Series E: $200 million (August 2023) - Series F and follow-up round: Over $1 billion (2024) The company's valuation exceeded $5 billion following its 2024 funding rounds. ### Customer Base and Additional Services Zepto primarily targets busy individuals aged 18-35 in densely populated urban areas. The company offers competitive pricing, consistent delivery times, and a user-friendly app. In addition to its core grocery delivery service, Zepto has introduced a paid membership program, which had over 4 million subscribers as of April 2024. ### Challenges and Workforce While Zepto has achieved remarkable success, it has faced criticism regarding the treatment of delivery workers and concerns about app design practices. The company employs over 3 million gig workers, contributing significantly to India's delivery sector workforce. Zepto's rapid growth and innovative approach have positioned it as a major player in India's quick-commerce industry, despite challenges and intense competition in the market.

A

African Development Bank

The African Development Bank (AfDB), also known as the Banque Africaine de Développement (BAD), is a multilateral development finance institution dedicated to promoting economic and social progress in Africa. Established in 1964, the AfDB has grown to become a crucial player in Africa's development landscape. ## Mission and Structure The AfDB's primary mission is to contribute to the economic development and social progress of its regional member countries (RMCs) by promoting public and private capital investment in projects and programs that enhance economic and social development. The AfDB Group consists of three main entities: 1. African Development Bank (AfDB): The parent organization, providing financing for public and private projects and programs. 2. African Development Fund (ADF): Established in 1972, it offers concessional financing to low-income RMCs. 3. Nigeria Trust Fund (NTF): Set up by the Nigerian government in 1976, it co-finances programs with the AfDB and ADF. ## Membership and Funding The AfDB has 81 member countries, including 54 African countries (regional members) and 27 non-African countries (non-regional members). The bank's resources come from subscriptions by member countries, borrowings on international capital markets, loan repayments, and income. With a AAA rating from major financial rating agencies, the AfDB can secure funds on favorable terms. ## Key Focus Areas The AfDB concentrates its efforts on several critical sectors: - Infrastructure Development: Transport, energy, and water systems - Regional Economic Integration - Private Sector Development - Governance and Accountability - Skills and Technology - Gender Equality - Environmental and Climate Initiatives ## Governance and Impact The AfDB is governed by a Board of Governors, with each member country represented by a Governor and an Alternate. The Board of Directors, elected by the Board of Governors, is responsible for the bank's general operations. Since its inception, the AfDB has financed over 2,885 operations, totaling $47.5 billion, significantly contributing to Africa's development through various projects and initiatives. The African Development Bank continues to play a vital role in shaping Africa's economic landscape, fostering sustainable development, and improving the lives of millions across the continent.

T

TPG

TPG Inc., formerly known as Texas Pacific Group and TPG Capital, is a leading global alternative asset manager with a rich history and diverse investment strategies. Founded in 1992 by David Bonderman, James Coulter, and William S. Price III, TPG has grown from its first office in San Francisco to a global entity managing approximately $239 billion in assets. TPG operates through several distinct investment platforms: - TPG Capital: Large-scale control-oriented private equity investing ($73 billion AUM) - TPG Growth: Growth equity and middle market private equity investing ($27 billion AUM) - TPG Impact: Private equity focusing on societal and financial outcomes ($25 billion AUM) - TPG Angelo Gordon: Global credit and real estate investing ($88 billion AUM) The firm invests in a wide range of industries, including consumer/retail, media and telecommunications, industrials, technology, travel, leisure, and healthcare. TPG has a strong presence in emerging markets, particularly in Asia and Latin America. TPG's portfolio includes over 300 active companies across more than 30 countries. Notable transactions include Continental Airlines, Burger King, and Petco. In 2023, TPG acquired Angelo Gordon to expand its credit and real estate capabilities. Led by CEO Jon Winkelried since 2021, TPG is known for its culture of innovation, organic growth, and collaboration. The firm became publicly listed on NASDAQ under the ticker symbol TPG in January 2022. Recent developments include raising $7.3 billion for its Rise Climate fund in 2022, focusing on climate investments as part of its Impact strategy. TPG's approach is characterized by its principled focus on innovation, organic growth, and a collaborative culture, positioning it as a significant player in the global alternative asset management landscape.